Annexon (ANNX)
Annexon on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
31.6M
Short interest
settlement 2026-10-15
10.3
Days to cover
+1.4 days vs prior
47.2%
Short share of volume
2026-11-02
449
Fails to deliver
settlement 2026-09-22
Mon 9 Nov
Next earnings
estimated date
$100K
Insider flow, 90 days
1 buys, 0 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in ANNX is 31,627,401 shares, down 1,244,594 shares over the last month. Over the last 48 readings it ranged from 7,144,909 shares (15 November 2024) to 32,871,995 shares (15 September 2026). The latest reading sits at the top of that range. At the reported average volume of 3.1M shares a day that is 10.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/annx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 31,627,401 | -1.2% | 3,069,100 | 10.31 |
| 2026-09-30 | 32,009,914 | -2.6% | 3,597,520 | 8.90 |
| 2026-09-15 | 32,871,995 | +2.4% | 2,813,644 | 11.68 |
| 2026-08-31 | 32,094,286 | -1.5% | 2,524,025 | 12.72 |
| 2026-08-14 | 32,583,299 | +5.9% | 2,474,096 | 13.17 |
| 2026-07-31 | 30,772,146 | +3.2% | 2,944,760 | 10.45 |
| 2026-07-15 | 29,827,889 | +0.8% | 5,194,732 | 5.74 |
| 2026-06-30 | 29,604,763 | +12.2% | 5,460,764 | 5.42 |
| 2026-06-15 | 26,388,542 | +2.1% | 2,836,987 | 9.30 |
| 2026-05-29 | 25,834,304 | +6.4% | 2,654,616 | 9.73 |
| 2026-05-15 | 24,288,025 | +3.6% | 1,828,637 | 13.28 |
| 2026-04-30 | 23,443,455 | +19.1% | 2,148,863 | 10.91 |
| 2026-04-15 | 19,675,024 | +5.6% | 2,498,716 | 7.87 |
| 2026-03-31 | 18,637,378 | +13.6% | 3,258,014 | 5.72 |
| 2026-03-13 | 16,401,412 | +3.1% | 2,682,175 | 6.11 |
| 2026-02-27 | 15,901,379 | -1.4% | 2,274,965 | 6.99 |
| 2026-02-13 | 16,131,493 | -6.3% | 2,077,900 | 7.76 |
| 2026-01-30 | 17,217,855 | -6.6% | 2,249,084 | 7.66 |
| 2026-01-15 | 18,436,024 | +13.2% | 3,007,528 | 6.13 |
| 2025-12-31 | 16,284,598 | +33.4% | 2,721,550 | 5.98 |
| 2025-12-15 | 12,204,357 | +16.2% | 2,809,921 | 4.34 |
| 2025-11-28 | 10,504,723 | +20.3% | 4,468,060 | 2.35 |
| 2025-11-14 | 8,731,864 | -4.6% | 1,926,347 | 4.53 |
| 2025-10-31 | 9,151,927 | -10.2% | 2,086,561 | 4.39 |
| 2025-10-15 | 10,188,623 | +0.1% | 1,609,579 | 6.33 |
| 2025-09-30 | 10,178,665 | +6.4% | 2,640,582 | 3.85 |
| 2025-09-15 | 9,569,516 | -5.6% | 2,022,985 | 4.73 |
| 2025-08-29 | 10,136,355 | +2.7% | 1,308,961 | 7.74 |
| 2025-08-15 | 9,871,091 | +2.7% | 1,070,470 | 9.22 |
| 2025-07-31 | 9,608,251 | -8.1% | 1,398,466 | 6.87 |
| 2025-07-15 | 10,452,762 | +4.0% | 2,302,577 | 4.54 |
| 2025-06-30 | 10,053,356 | -0.7% | 1,272,011 | 7.90 |
| 2025-06-13 | 10,122,943 | +1.5% | 1,448,080 | 6.99 |
| 2025-05-30 | 9,969,617 | -1.6% | 1,453,319 | 6.86 |
| 2025-05-15 | 10,127,479 | +9.2% | 1,253,108 | 8.08 |
| 2025-04-30 | 9,273,824 | +7.2% | 1,875,637 | 4.94 |
| 2025-04-15 | 8,652,374 | +5.0% | 2,293,143 | 3.77 |
| 2025-03-31 | 8,242,519 | -25.9% | 2,400,367 | 3.43 |
| 2025-03-14 | 11,118,280 | +2.0% | 1,003,742 | 11.08 |
| 2025-02-28 | 10,895,296 | +7.9% | 1,021,813 | 10.66 |
| 2025-02-14 | 10,100,209 | +0.1% | 1,122,722 | 9.00 |
| 2025-01-31 | 10,086,385 | +8.2% | 1,761,777 | 5.73 |
| 2025-01-15 | 9,321,910 | +3.8% | 1,251,634 | 7.45 |
| 2024-12-31 | 8,978,503 | +23.6% | 1,720,322 | 5.22 |
| 2024-12-13 | 7,263,052 | -2.3% | 1,068,910 | 6.79 |
| 2024-11-29 | 7,429,906 | +4.0% | 1,512,472 | 4.91 |
| 2024-11-15 | 7,144,909 | -8.0% | 1,521,676 | 4.70 |
| 2024-10-31 | 7,769,658 | -12.9% | 922,608 | 8.42 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of ANNX volume is 47.2%, down 2.0 points over the last five sessions. Over the last 30 readings it ranged from 24.6% (22 October 2026) to 76.6% (14 October 2026). The latest reading is in line with the 30-session average of 47.4%, on 736K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 347K | 736K | 47.2% | 4,512 |
| 2026-10-30 | 325K | 1.0M | 32.0% | 1,371 |
| 2026-10-29 | 344K | 968K | 35.5% | 0 |
| 2026-10-28 | 382K | 1.1M | 35.2% | 2,705 |
| 2026-10-27 | 257K | 1.0M | 25.0% | 0 |
| 2026-10-26 | 450K | 915K | 49.1% | 268 |
| 2026-10-23 | 499K | 879K | 56.8% | 9,344 |
| 2026-10-22 | 403K | 1.6M | 24.6% | 403 |
| 2026-10-21 | 1.6M | 2.3M | 68.4% | 909 |
| 2026-10-20 | 1.2M | 2.5M | 49.1% | 2,964 |
| 2026-10-19 | 974K | 2.8M | 35.3% | 1,851 |
| 2026-10-16 | 713K | 2.2M | 32.0% | 3,439 |
| 2026-10-15 | 559K | 949K | 58.9% | 5,166 |
| 2026-10-14 | 1.2M | 1.5M | 76.6% | 300 |
| 2026-10-13 | 829K | 1.3M | 64.3% | 16 |
| 2026-10-12 | 409K | 770K | 53.1% | 0 |
| 2026-10-09 | 211K | 508K | 41.5% | 0 |
| 2026-10-08 | 414K | 896K | 46.2% | 0 |
| 2026-10-07 | 344K | 913K | 37.6% | 0 |
| 2026-10-06 | 366K | 1.0M | 35.1% | 5,717 |
| 2026-10-05 | 411K | 893K | 46.0% | 0 |
| 2026-10-02 | 701K | 2.0M | 34.9% | 0 |
| 2026-10-01 | 729K | 1.7M | 41.9% | 5,692 |
| 2026-09-30 | 1.0M | 1.7M | 58.6% | 96 |
| 2026-09-29 | 1.0M | 1.5M | 69.1% | 4 |
| 2026-09-28 | 1.1M | 3.0M | 38.0% | 48 |
| 2026-09-25 | 654K | 1.9M | 33.6% | 193 |
| 2026-09-24 | 508K | 760K | 66.9% | 3,244 |
| 2026-09-23 | 616K | 911K | 67.7% | 13 |
| 2026-09-22 | 377K | 614K | 61.4% | 25 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 22 September 2026, the fails-to-deliver balance in ANNX is 449 shares, down 4,266 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (3 November 2025) to 1,000,732 shares (29 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-22 | 449 | $4.22 | $2K |
| 2026-09-08 | 4,715 | $4.87 | $23K |
| 2026-07-27 | 7 | $5.22 | $37 |
| 2026-07-16 | 93 | $6.50 | $605 |
| 2026-07-09 | 615,860 | $5.96 | $3.7M |
| 2026-07-08 | 10,018 | $6.43 | $64K |
| 2026-06-30 | 225,796 | $5.57 | $1.3M |
| 2026-06-29 | 1,000,732 | $5.48 | $5.5M |
| 2026-06-25 | 1,056 | $5.30 | $6K |
| 2026-05-22 | 126,348 | $5.44 | $687K |
| 2026-04-24 | 87,654 | $6.06 | $531K |
| 2026-03-24 | 69 | $5.37 | $371 |
| 2026-03-18 | 2,885 | $5.61 | $16K |
| 2026-03-10 | 97 | $5.59 | $542 |
| 2026-02-27 | 291,060 | $5.38 | $1.6M |
| 2026-02-23 | 571 | $4.90 | $3K |
| 2026-01-13 | 691 | $5.56 | $4K |
| 2026-01-12 | 32 | $5.25 | $168 |
| 2025-12-24 | 80,500 | $5.11 | $411K |
| 2025-12-22 | 18,982 | $5.17 | $98K |
| 2025-11-25 | 39 | $4.51 | $176 |
| 2025-11-24 | 120 | $4.27 | $512 |
| 2025-11-21 | 1,893 | $4.27 | $8K |
| 2025-11-13 | 63,777 | $2.84 | $181K |
| 2025-11-06 | 362 | $3.01 | $1K |
| 2025-11-03 | 1 | $3.16 | $3 |
| 2025-10-29 | 17,825 | $3.45 | $61K |
| 2025-10-28 | 17,825 | $3.54 | $63K |
| 2025-10-16 | 88 | $3.04 | $268 |
| 2025-10-14 | 7,803 | $3.01 | $23K |
Insider trades
SEC Form 4, newest first. JSONInsiders at ANNX reported 1 open-market buy worth $100K in the last 90 days and no open-market sells. Latest filing: Love Douglas (PRESIDENT AND CEO) on 2026-09-24.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-24 | Love Douglas | PRESIDENT AND CEO | Buy | 26K | $3.83 | $100K | 390K |
| 2026-06-11 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Exercise or conversion | 31K | $1.85 | $57K | 185K |
| 2026-05-28 | Satter Muneer A | Director | Buy | 613K | $5.41 | $3.3M | 10.3M |
| 2026-05-11 | Carson William H. | Director | Buy | 8K | $5.78 | $46K | 78K |
| 2026-04-10 | Carson William H. | Director | Buy | 8K | $6.20 | $50K | 70K |
| 2026-03-10 | Carson William H. | Director | Buy | 8K | $5.67 | $45K | 62K |
| 2026-03-02 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Sell | 6K | $5.42 | $30K | 154K |
| 2026-03-02 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Sell | 4K | $5.42 | $24K | 183K |
| 2026-03-02 | Dananberg Jamie | CHIEF MEDICAL OFFICER | Sell | 6K | $5.43 | $32K | 124K |
| 2026-03-02 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Sell | 6K | $5.42 | $30K | 171K |
| 2026-03-02 | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | Sell | 6K | $5.43 | $32K | 180K |
| 2026-02-19 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Grant | 63K | $0.00 | $0 | 160K |
| 2026-02-19 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Grant | 63K | $0.00 | $0 | 187K |
| 2026-02-19 | Dananberg Jamie | CHIEF MEDICAL OFFICER | Grant | 56K | $0.00 | $0 | 129K |
| 2026-02-19 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Grant | 63K | $0.00 | $0 | 176K |
| 2026-02-19 | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | Grant | 63K | $0.00 | $0 | 186K |
| 2026-02-18 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Sell | 8K | $5.11 | $40K | 97K |
| 2026-02-18 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Sell | 6K | $5.10 | $32K | 124K |
| 2026-02-18 | Dananberg Jamie | CHIEF MEDICAL OFFICER | Sell | 5K | $5.10 | $27K | 73K |
| 2026-02-18 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Sell | 8K | $5.11 | $40K | 114K |
| 2026-02-18 | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | Sell | 5K | $5.10 | $27K | 123K |
| 2025-12-30 | Carson William H. | Director | Buy | 4K | $5.02 | $21K | 54K |
| 2025-12-01 | Carson William H. | Director | Buy | 4K | $4.47 | $18K | 50K |
| 2025-12-01 | Choi Jung | Director | Buy | 33K | $4.19 | $138K | 33K |
| 2025-11-21 | Satter Muneer A | Director | Buy | 423K | $4.28 | $1.8M | 9.7M |
| 2025-11-20 | Satter Muneer A | Director | Buy | 400K | $4.48 | $1.8M | 9.3M |
| 2025-11-19 | Satter Muneer A | Director | Buy | 500K | $3.94 | $2.0M | 8.9M |
| 2025-11-18 | Satter Muneer A | Director | Buy | 500K | $3.18 | $1.6M | 8.4M |
| 2025-11-17 | Satter Muneer A | Director | Buy | 500K | $2.99 | $1.5M | 7.9M |
| 2025-10-30 | Carson William H. | Director | Buy | 4K | $3.17 | $13K | 46K |
| 2025-09-30 | Carson William H. | Director | Buy | 4K | $3.05 | $13K | 42K |
| 2025-09-02 | Carson William H. | Director | Buy | 4K | $2.09 | $9K | 38K |
| 2025-07-30 | Carson William H. | Director | Buy | 4K | $2.43 | $10K | 34K |
| 2025-07-14 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Sell | 1K | $2.58 | $3K | 105K |
| 2025-07-14 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Sell | 1K | $2.58 | $3K | 122K |
| 2025-07-14 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Sell | 853 | $2.61 | $2K | 131K |
| 2025-06-30 | Carson William H. | Director | Buy | 4K | $2.46 | $10K | 30K |
| 2025-02-18 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Sell | 7K | $2.92 | $20K | 78K |
| 2025-02-18 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Sell | 7K | $2.95 | $20K | 87K |
| 2025-02-18 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Sell | 8K | $2.91 | $24K | 61K |
| 2025-02-18 | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | Sell | 6K | $2.97 | $16K | 84K |
| 2025-02-18 | Dananberg Jamie | CHIEF MEDICAL OFFICER | Sell | 6K | $2.96 | $16K | 33K |
| 2025-02-13 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Sell | 1K | $2.99 | $4K | 93K |
| 2025-02-13 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Sell | 2K | $2.99 | $5K | 70K |
| 2025-02-13 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Sell | 2K | $2.98 | $5K | 85K |
| 2025-02-13 | Love Douglas | PRESIDENT AND CEO | Sell | 5K | $2.95 | $15K | 352K |
| 2025-01-06 | Love Douglas | PRESIDENT AND CEO | Exercise or conversion | 38K | $1.41 | $54K | 357K |
| 2024-12-02 | Carson William H. | Director | Buy | 3K | $5.33 | $17K | 26K |
| 2024-10-30 | Love Douglas | PRESIDENT AND CEO | Exercise or conversion | 36K | $1.85 | $67K | 311K |
| 2024-10-30 | Love Douglas | PRESIDENT AND CEO | Exercise or conversion | 78K | $1.85 | $145K | 275K |
| 2024-10-15 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Sell | 5K | $7.41 | $40K | 71K |
| 2024-10-15 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Exercise or conversion | 5K | $1.85 | $10K | 77K |
| 2024-10-01 | Carson William H. | Director | Buy | 3K | $5.97 | $19K | 22K |
| 2024-09-19 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Sell | 5K | $7.10 | $32K | 0 |
| 2024-09-12 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Sell | 6K | $6.16 | $34K | 5K |
| 2024-09-05 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Sell | 6K | $5.64 | $31K | 10K |
| 2024-09-03 | Carson William H. | Director | Buy | 3K | $5.48 | $18K | 19K |
| 2024-08-29 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Sell | 6K | $5.95 | $33K | 16K |
| 2024-08-01 | Carson William H. | Director | Buy | 3K | $6.24 | $20K | 16K |
| 2024-07-15 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Sell | 1K | $6.02 | $7K | 71K |
| 2024-07-15 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Sell | 1K | $6.03 | $7K | 86K |
| 2024-07-15 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Sell | 784 | $6.02 | $5K | 95K |
| 2024-07-01 | Carson William H. | Director | Buy | 3K | $5.00 | $16K | 13K |
| 2024-06-03 | Carson William H. | Director | Buy | 3K | $4.83 | $15K | 10K |
| 2024-05-01 | Carson William H. | Director | Buy | 3K | $4.68 | $15K | 6K |
| 2024-04-08 | Carson William H. | Director | Buy | 3K | $6.07 | $19K | 3K |
| 2024-02-27 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Grant | 45K | $0.00 | $0 | 132K |
| 2024-02-27 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Grant | 45K | $0.00 | $0 | 106K |
| 2024-02-27 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Grant | 45K | $0.00 | $0 | 123K |
| 2024-02-27 | Dananberg Jamie | CHIEF MEDICAL OFFICER | Grant | 45K | $0.00 | $0 | 78K |
| 2024-02-27 | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | Grant | 45K | $0.00 | $0 | 129K |
| 2024-02-20 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Sell | 3K | $5.53 | $14K | 82K |
| 2024-02-20 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Sell | 2K | $5.48 | $11K | 86K |
| 2024-02-20 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Sell | 3K | $5.51 | $14K | 72K |
| 2024-02-16 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Grant | 39K | $0.00 | $0 | 85K |
| 2024-02-16 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Grant | 39K | $0.00 | $0 | 88K |
| 2024-02-16 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Grant | 39K | $0.00 | $0 | 75K |
| 2024-02-16 | ARTIS DEAN RICHARD | EVP & CHIEF SCIENTIFIC OFFICER | Grant | 39K | $0.00 | $0 | 89K |
| 2024-02-16 | Dananberg Jamie | CHIEF MEDICAL OFFICER | Grant | 39K | $0.00 | $0 | 39K |
| 2024-02-12 | Yednock Ted | EVP & CHIEF INNOVATION OFFICER | Sell | 2K | $5.54 | $10K | 36K |
| 2024-02-12 | Lew Jennifer | EVP & CHIEF FINANCIAL OFFICER | Sell | 2K | $5.54 | $10K | 46K |
| 2024-02-12 | Love Douglas | PRESIDENT AND CEO | Sell | 6K | $5.54 | $32K | 196K |
| 2024-02-12 | Overdorf Michael | EVP & CHIEF BUSINESS OFFICER | Sell | 1K | $5.53 | $7K | 49K |
| 2023-12-27 | Yednock Ted | EVP & Chief Innovation Officer | Exercise or conversion | 11K | $1.41 | $15K | 49K |
| 2023-12-27 | Yednock Ted | EVP & Chief Innovation Officer | Exercise or conversion | 10K | $1.85 | $19K | 59K |
| 2023-12-27 | Yednock Ted | EVP & Chief Innovation Officer | Sell | 21K | $4.52 | $95K | 38K |
| 2023-12-27 | Yednock Ted | EVP & Chief Innovation Officer | Exercise or conversion | 11K | $1.41 | $15K | 11K |
| 2023-12-27 | Yednock Ted | EVP & Chief Innovation Officer | Sell | 21K | $4.52 | $95K | 0 |
| 2023-12-27 | Yednock Ted | EVP & Chief Innovation Officer | Exercise or conversion | 10K | $1.85 | $19K | 21K |
| 2023-12-26 | Satter Muneer A | Director,TenPercentOwner | Buy | 350K | $2.88 | $1.0M | 7.4M |
| 2023-07-11 | Lew Jennifer | EVP & Chief Financial Officer | Sell | 1K | $3.84 | $4K | 47K |
| 2023-07-11 | Overdorf Michael | EVP & Chief Business Officer | Sell | 978 | $3.84 | $4K | 46K |
| 2023-07-11 | Yednock Ted | EVP & Chief Innovation Officer | Sell | 1K | $3.84 | $4K | 38K |
| 2023-05-25 | Bain Capital Life Sciences Investors, LLC | TenPercentOwner | Buy | 300K | $2.13 | $639K | 5.7M |
| 2023-02-16 | Lew Jennifer | EVP & Chief Financial Officer | Grant | 19K | $0.00 | $0 | 49K |
| 2023-02-16 | Overdorf Michael | EVP & Chief Business Officer | Grant | 19K | $0.00 | $0 | 47K |
| 2023-02-15 | Love Douglas | President & CEO | Sell | 7K | $5.87 | $39K | 198K |
| 2023-02-14 | Lew Jennifer | EVP & Chief Financial Officer | Sell | 166 | $6.30 | $1K | 30K |
| 2023-02-14 | Overdorf Michael | EVP & Chief Business Officer | Sell | 144 | $6.30 | $907 | 28K |
| 2023-02-13 | Lew Jennifer | EVP & Chief Financial Officer | Sell | 2K | $6.31 | $11K | 30K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON13 Form 144 notices on file for ANNX worth $342K at the prices reported; 1 in the last 90 days worth $11K. Latest: WIGGANS THOMAS G filed on 2026-08-13 to sell 2,000 shares ($11K) from 2026-08-13.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-08-13 | WIGGANS THOMAS GFormer Director | 2K | $11K | 0.001% | 2026-08-13 | Fidelity Brokerage Services LLC |
| 2026-07-15 | WIGGANS THOMAS GFormer Director | 2K | $13K | 0.001% | 2026-07-15 | Fidelity Brokerage Services LLC |
| 2026-07-14 | WIGGANS THOMAS GFormer Director | 1K | $6K | 0.001% | 2026-07-14 | Fidelity Brokerage Services LLC |
| 2026-03-02 | Yednock TedOfficer | 6K | $30K | 0.005% | 2026-03-02 | Fidelity Brokerage Services LLC |
| 2026-03-02 | Overdorf MichaelOfficer | 4K | $24K | 0.004% | 2026-03-02 | Fidelity Brokerage Services LLC |
| 2026-03-02 | Dananberg JamieOfficer | 6K | $32K | 0.005% | 2026-03-02 | Fidelity Brokerage Services LLC |
| 2026-03-02 | Lew JenniferOfficer | 6K | $30K | 0.005% | 2026-03-02 | Fidelity Brokerage Services LLC |
| 2026-03-02 | ARTIS DEAN RICHARDOfficer | 6K | $32K | 0.005% | 2026-03-02 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Lew JenniferOfficer | 8K | $40K | 0.007% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Yednock TedOfficer | 8K | $40K | 0.007% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Overdorf MichaelOfficer | 6K | $32K | 0.005% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-18 | Dananberg JamieOfficer | 5K | $27K | 0.004% | 2026-02-18 | Fidelity Brokerage Services LLC |
| 2026-02-18 | ARTIS DEAN RICHARDOfficer | 5K | $27K | 0.004% | 2026-02-18 | Fidelity Brokerage Services LLC |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON12 holders report 5% or more of ANNX in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is Abigail P. Johnson at 11.9% of the class (19,518,496 shares), filed 2026-07-08 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-07 | 13G | STATE STREET CORPORATIONparent holding company | 9.8M | 6.0% | 2026-06-30 |
| 2026-07-27 | 13G/Ano. 2 | BlackRock, Inc.parent holding company | 13.1M | 8.0% | 2026-06-30 |
| 2026-07-08 | 13G/Ano. 6 | Jeremy C. Greenparent holding company, individual | 17.9M | 9.9% | 2026-07-01 |
| 2026-07-08 | 13G/Ano. 6 | Redmile Group, LLCinvestment adviser, other entity | 17.9M | 9.9% | 2026-07-01 |
| 2026-07-08 | 13G/Ano. 6 | RedCo II Offshore SPV LLCnon-US institution, other entity | 9.8M | 5.5% | 2026-07-01 |
| 2026-07-08 | 13G/Ano. 6 | Abigail P. Johnsonindividual | 19.5M | 11.9% | 2026-06-30 |
| 2026-07-08 | 13G/Ano. 6 | FMR LLCparent holding company | 19.5M | 11.9% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 4 | BVF PARTNERS L P/ILinvestment adviser, partnership | 8.7M | 5.4% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | BVF INC/ILcorporation | 8.7M | 5.4% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | LAMPERT MARK Nindividual | 8.7M | 5.4% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | BVF GP HOLDINGS LLCother entity | 8.0M | 5.0% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | BVF I GP LLCother entity | 4.6M | 2.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | BIOTECHNOLOGY VALUE FUND L Ppartnership | 4.6M | 2.9% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | BVF II GP LLCother entity | 3.4M | 2.1% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | BIOTECHNOLOGY VALUE FUND II LPpartnership | 3.4M | 2.1% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | Biotechnology Value Trading Fund OS LPpartnership | 523K | 0.3% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 4 | BVF Partners OS Ltd.corporation | 523K | 0.3% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 1 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-17 | 13G/Ano. 5 | Redmile Biopharma Investments II, L.P.partnership | 7.3M | 4.7% | 2025-12-31 |
| 2025-11-21 | 13D/Ano. 2 | Satter Muneer Aindividual | 10.4M | 7.2% | 2025-11-19 |
13F holders
Tracked managers holding ANNX at their latest 13F. JSON7 of the 30 tracked managers held ANNX at their latest 13F, $29.1M in total at quarter-end prices. Point72 Asset Management is the largest at $7.9M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 6 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 1.4M | $7.9M | 0.01% | -489K |
| Millennium Management | 2026-06-30 | 1.2M | $6.8M | 0.00% | -54K |
| AQR Capital Management | 2026-06-30 | 692K | $4.0M | 0.00% | -85K |
| Citadel Advisors | 2026-06-30 | 597K | $3.4M | 0.00% | -4K |
| Two Sigma Investments | 2026-06-30 | 513K | $2.9M | 0.00% | +41K |
| Renaissance Technologies | 2026-06-30 | 459K | $2.6M | 0.00% | -85K |
| D. E. Shaw & Co. | 2026-06-30 | 265K | $1.5M | 0.00% | -438K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Annexon in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Annexon (ANNX), SEC CIK 1528115, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-22.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-08-13.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-12.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-24.JSON and CSV
- Company record
- EDGAR filing index for CIK 1528115Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of ANNX is sold short?
31,627,401 shares were held short at the 2026-10-15 settlement, 10.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is ANNX's daily short volume?
On 2026-11-02, 347,125 of the 736,006 ANNX shares reported to FINRA were sold short, 47.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does ANNX have fails to deliver?
The SEC's latest file shows 449 ANNX shares failed to deliver at settlement 2026-09-22. Fails are reported per settlement date and published twice a month with a lag.
Are ANNX insiders buying or selling?
Insiders at ANNX reported 1 open-market buy worth $100K in the last 90 days and no open-market sells. Latest filing: Love Douglas (PRESIDENT AND CEO) on 2026-09-24.
Have ANNX insiders filed to sell?
13 Form 144 notices on file for ANNX worth $342K at the prices reported; 1 in the last 90 days worth $11K. Latest: WIGGANS THOMAS G filed on 2026-08-13 to sell 2,000 shares ($11K) from 2026-08-13.
Who owns 5% or more of ANNX?
12 holders report 5% or more of ANNX in their latest filing, 1 on Schedule 13D (active intent). The largest reported stake is Abigail P. Johnson at 11.9% of the class (19,518,496 shares), filed 2026-07-08 for an event on 2026-06-30.
Which tracked 13F managers own ANNX?
7 of the 30 tracked 13F managers held ANNX shares at their latest filing, $29.1M in all. The largest: Steve Cohen's Point72 Asset Management (1.4M shares, $7.9M), Izzy Englander's Millennium Management (1.2M shares, $6.8M), Cliff Asness's AQR Capital Management (692K shares, $4.0M), Ken Griffin's Citadel Advisors (597K shares, $3.4M), Two Sigma Investments (513K shares, $2.9M), Renaissance Technologies (459K shares, $2.6M). The table above lists all 7.
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.